Company intelligence / Profile preview

Tectonic Therapeutic

Watertown, Massachusetts, United Statestectonicplatforms.com ↗

Ownership: Private
Development stage: Other

Overview

Tectonic’s lead program, TX45, is a Fc-relaxin fusion protein targeting the relaxin receptor for Group 2 pulmonary hypertension. Interim Phase 1b results showed a 17.9% reduction in pulmonary capillary wedge pressure and >30% reduction in pulmonary vascular resistance among patients with more severe disease. The company is advancing to Part B of its Phase 1b trial and has initiated a Phase 2 APEX trial. Another candidate, TX2100, targets HHT and is expected to enter clinical trials by late 2025 or early 2026.

Therapeutic areas: CardiovascularRare Diseases
Modalities: ProteinMonoclonal antibodyBiologic
Industry: Biotech

Beyond the preview

Go deeper on Tectonic Therapeutic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tectonic Therapeutic.

Explore the full profile